Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D09PWJ
|
|||
| Former ID |
DIB020367
|
|||
| Drug Name |
ML218
|
|||
| Synonyms |
ML-218; ML 218
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C19H26Cl2N2O
|
|||
| Canonical SMILES |
CC(C)(C)CCN1CC2C(C1)C2CNC(=O)C3=CC(=CC(=C3)Cl)Cl
|
|||
| InChI |
1S/C19H26Cl2N2O/c1-19(2,3)4-5-23-10-16-15(17(16)11-23)9-22-18(24)12-6-13(20)8-14(21)7-12/h6-8,15-17H,4-5,9-11H2,1-3H3,(H,22,24)/t15?,16-,17+
|
|||
| InChIKey |
GSJIGYLGKSBYBC-ALOPSCKCSA-N
|
|||
| PubChem Compound ID | ||||
| ChEBI ID |
CHEBI:91745
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Voltage-gated calcium channel alpha Cav3.1 (CACNA1G) | Target Info | Blocker (channel blocker) | [2] |
| Voltage-gated calcium channel alpha Cav3.2 (CACNA1H) | Target Info | Blocker (channel blocker) | [2] | |
| Voltage-gated calcium channel alpha Cav3.3 (CACNA1I) | Target Info | Blocker (channel blocker) | [2] | |
| KEGG Pathway | MAPK signaling pathway | |||
| Calcium signaling pathway | ||||
| Circadian entrainment | ||||
| Type II diabetes mellitus | ||||
| MAPK signaling pathway | ||||
| Calcium signaling pathway | ||||
| Circadian entrainment | ||||
| Panther Pathway | Endogenous cannabinoid signaling | |||
| GABA-B receptor II signaling | ||||
| Nicotine pharmacodynamics pathway | ||||
| Pathwhiz Pathway | Muscle/Heart Contraction | |||
| Pathway Interaction Database | Regulation of nuclear beta catenin signaling and target gene transcription | |||
| Reactome | NCAM1 interactions | |||
| WikiPathways | Corticotropin-releasing hormone | |||
| NCAM signaling for neurite out-growth | ||||
| Nicotine Activity on Chromaffin Cells | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7720). | |||
| REF 2 | The Discovery and Characterization of ML218: A Novel, Centrally Active T-Type Calcium Channel Inhibitor with Robust Effects in STN Neurons and in a Rodent Model of Parkinson's Disease. ACS Chem Neurosci. 2011 Dec 21;2(12):730-742. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.